Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $40.8571.

A number of research analysts have recently issued reports on the stock. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Friday, July 17th. B. Riley Financial began coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th. Finally, Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th.

Lyell Immunopharma Price Performance

Shares of NASDAQ LYEL opened at $15.76 on Thursday. Lyell Immunopharma has a 1-year low of $10.49 and a 1-year high of $45.00. The business has a fifty day moving average price of $13.61 and a 200 day moving average price of $18.39. The stock has a market capitalization of $386.12 million, a P/E ratio of -1.23 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.94) by $0.02. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. As a group, equities research analysts anticipate that Lyell Immunopharma will post -7.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. venBio Partners LLC acquired a new stake in Lyell Immunopharma during the second quarter worth about $4,744,643,000. Bank of New York Mellon Corp purchased a new stake in Lyell Immunopharma during the second quarter worth $347,000. Bank of America Corp DE boosted its holdings in Lyell Immunopharma by 314.2% during the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after buying an additional 25,276 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Lyell Immunopharma by 194.8% in the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after buying an additional 76,921 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma in the first quarter worth about $445,000. 66.05% of the stock is owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.